Citi lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $80 and keeps a Buy rating on the shares post the Q3 report The firm says the company’s headwinds will be temporary but acknowledges the “low-quality results.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target lowered to $75 from $95 at Canaccord
- Exact Sciences Reports Strong Q3 Performance and Pipeline Advances
- Closing Bell Movers: Exact Sciences falls 30% after results, guidance cut
- Exact Sciences reports Q3 EPS (21c), consensus (21c)
- Exact Sciences cuts FY24 revenue view to $2.73B-$2.75B, consensus $2.83B